Table 3.
Prognostic and predictive biomarkers in Renal Cell Carcinoma.
| Biomarker | Results | Association with | References |
|---|---|---|---|
| IHC expression of p-S6, p-S6K1, p-AKT, and p21 | NA | No association with response to temsirolimus/everolimus | (37) |
| Negative IHC expression for BAP1 | OR = 4.0, 95% CI = 1.4–11.9, p = 0.011 | Better mTOR inhibitor response | (37) |
| Negative IHC expression for PBRM1 | OR = 3.9, 95% CI = 1.2–12.8, p = 0.025 | Better mTOR inhibitor response | (37) |
| Gene alterations in BAP1 | HR 1.7; 95% CI 1.1–2.5, p = 0.01 | Worse OS | (38) |
| Gene alterations in PBRM1 | HR = 0.6; 95%CI 0.4–0.8, p = 0.001 | Better OS | (38) |
| Gene alterations in KDM5C | HR = 0.4; 95%CI 0.2–0.8, p = 0.007 | Better OS | (38) |
| SETD2, TP53, and VHL | NA (p > 0.4) | Not associated with prognosis | (38) |
| PBRM1 wild type + gene alterations BAP1 | 37 vs. 50 months, HR 1.9, 95% CI 1.2–2.8, p = 0.004 | Worse OS | (38) |
| PDCD1, CTLA4, and TLR9 | NA | Worse OS | (16) |
| 9p deletion | HR 4.323; p = 0.021 HR 4.603; p = 0.007 | High risk of recurrence and RCC-specific mortality | (18) |